Nejm plus

Research Open access Published: 27 November 2021 Audrey De Jong1, Gerald Chanques1, Emmanuel Futier2, Elie Azoulay3, Nicolas Molinari4,5 & …Samir Jaber1,6 Annals of Intensive Care volume 11, Article number: 165 (2021) Cite this article 3346 Accesses 7 Citations 4 Altmetric Metrics details AbstractBackgroundCritical care randomized controlled trials (RCTs) are often published in high-impact journals, whether general journals [the New England Journal of Medicine (NEJM), The Lancet, the Journal of the American Medical Association (JAMA)] or critical care journals [Intensive Care Medicine (ICM), the American Journal of Respiratory and Critical Care Medicine (AJRCCM), Critical Care Medicine (CCM)]. As rejection occurs in up to 97% of cases, it might be appropriate to assess pre-submission probability of being published. The objective of this study was to develop and internally validate a simplified score predicting whether an ongoing trial stands a chance of being published in high-impact general journals.MethodsA cohort of critical care RCTs published between 1999 and 2018 in the three highest impact medical journals (NEJM, The Lancet, JAMA) or the three highest impact critical care journals (ICM, AJRCCM, CCM) was split into two samples (derivation cohort, validation cohort) to develop and internally validate the simplified score. Primary outcome was journal of publication assessed as high-impact general journal (NEJM, The Lancet, JAMA) or critical care journal (ICM, AJRCCM, CCM).ResultsA total of 968 critical care RCTs were included in the predictive cohort and split into a derivation cohort (n = 510) and a validation cohort (n = 458). In the derivation cohort, the sample size (P value P value = 0.01), mortality as primary outcome (P value = 0.002) or a composite item including mortality as primary outcome (P value = 0.004), and topic [ventilation (P value P value ConclusionsThe SCOTI score, developed and validated by split sample, accurately predicts the chances of a

Critical care RCT being published in high-impact general journals, compared to high-impact critical care journals. BackgroundSince the late twentieth century, evidence-based medicine has emerged as a new paradigm to produce knowledge and improve clinical practice [1]. Randomized controlled trials (RCTs) are considered as the pinnacle of evidence for evaluating new and existing interventions in medicine [2], as long as they are appropriately designed, conducted, and reported [3, 4]. They have been further promoted by the development of online databases, reviews, meta-analyses, and education of clinicians and students [5].Critical care is no exception. Many RCTs have been performed in this field and have often led to publications in the highest impact critical care journals, such as Intensive Care Medicine (ICM), the American Journal of Respiratory and Critical Care Medicine (AJRCCM), and Critical Care Medicine (CCM) [6,7,8]. Moreover, landmark trials have changed the management of critically ill patients [9,10,11,12]. Many of those studies have been published in the highest impact general journals: The New England Journal of Medicine (NEJM), The Lancet, and the Journal of the American Medical Association (JAMA).It is the final purpose of medical research to broadcast its results as widely as possible to health care practitioners to most impact the management of patients worldwide [13]. In this context, RCTs performed in the field of critical care aim to be published in the highest impact general journals [2]. As up to 97% of trials are rejected outright or post-review, it might be appropriate to assess pre-submission probability of being published. To our knowledge, no study has yet explored the factors associated with the publication of a critical care RCT in a high-impact general journal.We designed this cohort of studies to identify independent predictive factors of publication of a critical care RCT in a high-impact general journal (NEJM, Lancet, JAMA) compared

Answer: Numerous statin drugs including atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), and simvastatin (Zocor) are taken to help lower cholesterol levels. Some, but not all, of these cholesterol-lowering statin drugs can be affected by taking supplements and/or can affect your ability to absorb certain vitamins and minerals.Sign in as a member to learn how the following supplements or foods may affect, or be affected, by statins: berberine, CoQ10, curcumin (from turmeric), grapefruit juice, green tea, magnesium, niacin, red yeast rice, quercetin, soy isoflavones, St. John's wort, Tribulus terrestris, vitamin D, and vitamin K. + — 26 sources In addition the results of its expert testing, ConsumerLab uses only high-quality, evidence based, information sources. These sources include peer-reviewed studies and information from agencies such as the FDA and USDA, and the National Academy of Medicine. On evolving topics, studies from pre-print journals may be sourced. All of our content is reviewed by medical doctors and doctoral-level experts in pharmacology, toxicology, and chemistry. We continually update and medically review our information to keep our content trustworthy, accurate, and reliable. The following sources are referenced in this article: Alfaddagh, J Am Heart Ass 2017Andren, Eur J Clin Pharmacol 2007Bhatti, StatPearls [Internet] 2023Boden, NEJM 2011Carallo, Metab Syndr Relat Disord 2022Derosa, Drug Des Devel Ther 2019Diederichsen, Circulation 2022Eggerston, Scand J Prim Health Care 2007Guo, Eur J Clin Pharmacol 2012Hasific, JAAC Adv 2023Kim, Clin Ther 2018Landray, NEJM 2014Livalo (pitavastatinMartin, Curr Med Res Opin 2008Misaka, Eur J Clin Pharmacol 2018Okuyama, Expert Rev Clin Pharmacol 2015Park, Xenobiotica 2008Peyrel, J Clin Lipidol 2023Riyad, J App Biol Biotechnol 2022Wang, Front Pharmacol 2022Werba, J Food Drug Anal 2018Wu, Eur J Clin Pharmacol 2005Zeng, Front Nutr 2022Zhang, Exp Ther Med 2021Zhelyazkova-Savova, Kaohsiung J Med Sci 2021de Keyser, Pharmacogen Genom 2014 Join today to unlock all member benefits including full access to all CL Answers and over 1,400 reviews. Join NowAlready a member? Sign In Here. Join now at www.consumerlab.com/join/